Skip to content
Comparison

Trulicity (Dulaglutide) vs Ozempic (Semaglutide)

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly injectable GLP-1 receptor agonists FDA-approved for type 2 diabetes. Ozempic consistently produces greater A1C reduction (~1.5–1.8%) and significantly more weight loss (~6–9% vs ~3–5%) than Trulicity. The SELECT trial also established semaglutide's cardiovascular benefit in patients with obesity and CVD. However, Trulicity was the most prescribed GLP-1 worldwide for years due to its established safety profile (REWIND trial cardiovascular benefit), convenient pen device, and often better insurance coverage. Both medications are well-tolerated, and for many patients the choice comes down to cost, access, and A1C targets.

4.3(112 ratings)

Quick Answer

Ozempic (semaglutide) outperforms Trulicity (dulaglutide) on A1C reduction and weight loss — head-to-head trials (SUSTAIN 7) found semaglutide 1 mg reduced A1C ~0.4% more than dulaglutide 0.75 mg and produced about twice the weight loss. Both drugs have cardiovascular outcome trial data. Ozempic is typically the preferred choice for patients needing greater efficacy; Trulicity may suit patients with better formulary coverage or prior successful response.

Head-to-Head Comparison

CriteriaTrulicity (Dulaglutide)Ozempic (Semaglutide)
Active ingredientDulaglutide — GLP-1 analog fused to IgG4 Fc fragmentSemaglutide — fatty acid-conjugated GLP-1 analog
FDA approval year2014 (T2D); REWIND trial added CV indication in 20202017 (T2D: Ozempic); 2021 (obesity: Wegovy)
Available T2D doses0.75 mg and 1.5 mg weekly (fixed pen doses)0.5 mg, 1.0 mg, 2.0 mg weekly
A1C reduction (head-to-head)~1.1–1.4% (dulaglutide 0.75–1.5 mg)~1.5–1.8% (semaglutide 1.0 mg) — ~0.4% greater in SUSTAIN 7
Weight loss (head-to-head)~2.7–3.0 kg (dulaglutide 0.75–1.5 mg) in SUSTAIN 7~4.6–6.5 kg (semaglutide 0.5–1.0 mg) in SUSTAIN 7 — roughly twice
Cardiovascular outcomes12% MACE reduction (REWIND trial; broad T2D population including primary prevention)26% MACE reduction (SUSTAIN-6; T2D with high CV risk); 20% MACE reduction (SELECT, obesity)
Half-life~5 days~7 days
Pen deviceMulti-dose prefilled pen with hidden needle — no reconstitution neededSingle-dose prefilled pen with visible needle after cap removal
Nausea rate~12–15% (generally milder GI profile)~20–25% at 1.0 mg dose — more GI events in head-to-head trials
US list price (2026)~$900–$1,000/month~$935–$1,000/month
Generic/biosimilar availabilityNo generic as of 2026 (Trulicity patent expires ~2027)No generic as of 2026 (Ozempic patent expires ~2030)
Weight loss indicationNo separate obesity formulation; modest weight loss only at T2D dosesWegovy (2.4 mg) approved for obesity; significantly more weight loss

When to Choose Each

Choose Trulicity (Dulaglutide)

Patients already responding well to Trulicity with adequate glycemic control, those with better insurance coverage for dulaglutide, patients who prefer the pen device design, or lower-CV-risk patients needing the REWIND trial's broader primary prevention data.

Choose Ozempic (Semaglutide)

Patients needing greater A1C reduction or more significant weight loss, those with high cardiovascular risk (SUSTAIN-6 and SELECT trial benefit), patients who want an option to escalate to the Wegovy dose for obesity, or anyone starting GLP-1 therapy for the first time with no formulary restriction.

Verdict

For most patients with type 2 diabetes who can access either medication, Ozempic (semaglutide) demonstrates superior A1C reduction and weight loss in head-to-head trials, stronger cardiovascular outcomes data, and the option to escalate to higher doses (2 mg) for additional benefit. Trulicity (dulaglutide) remains a solid, well-tolerated option — particularly for patients who have used it successfully, have better insurance coverage for dulaglutide, or prefer its pen device. The REWIND trial cardiovascular data for dulaglutide is broader (includes primary CV prevention, unlike SUSTAIN-6), which may matter for lower-risk patients. The ultimate choice between Trulicity and Ozempic should be made with your endocrinologist or primary care provider based on your specific A1C target, cardiovascular history, weight goals, and formulary coverage.

References

  1. Semaglutide vs dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) (2018) — PubMed
  2. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) (2019) — PubMed
  3. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) (2016) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed
  5. Efficacy and safety of dulaglutide versus insulin glargine in patients with type 2 diabetes (AWARD-2) (2015) — PubMed
  6. Efficacy of semaglutide once weekly versus SGLT2 inhibitors in patients with type 2 diabetes (SUSTAIN 9) (2019) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which works better for weight loss — Trulicity or Ozempic?
Ozempic consistently produces greater weight loss than Trulicity. In the SUSTAIN 7 head-to-head trial, semaglutide 1.0 mg produced approximately 4.6 kg weight loss vs approximately 2.7 kg for dulaglutide 0.75 mg at 40 weeks — roughly twice as much. At higher Ozempic doses (2.0 mg), additional weight loss occurs. For patients who want maximum weight loss from a GLP-1, Ozempic (and especially Wegovy at 2.4 mg) is the stronger choice. Trulicity is less effective for weight management but remains a solid T2D drug.
Does Trulicity or Ozempic have better cardiovascular protection?
Both have cardiovascular outcome trial data. The REWIND trial showed dulaglutide reduced MACE by 12% in a broad T2D population (including lower-risk patients without established CVD). SUSTAIN-6 showed semaglutide reduced MACE by 26% in T2D patients with high CV risk. The SELECT trial showed semaglutide at the obesity dose reduced MACE by 20% in patients with obesity and established CVD. Semaglutide has a higher magnitude of CV event reduction in higher-risk populations; dulaglutide has data in a broader (lower-risk) population. Discuss your specific cardiovascular risk profile with your cardiologist.
Which has fewer side effects — Trulicity or Ozempic?
Trulicity generally produces milder GI side effects. In the SUSTAIN 7 head-to-head trial, semaglutide 1.0 mg produced somewhat more nausea, vomiting, and diarrhea than dulaglutide 0.75 mg. However, both have similar GI side effect profiles that peak during dose escalation and improve over time. Individual responses vary significantly — some patients tolerate Ozempic better than Trulicity. If GI side effects are a major concern, discuss titration strategies with your provider.
Can I switch from Trulicity to Ozempic?
Yes, switching is clinically common and generally straightforward. Patients who have plateaued on Trulicity or need better glycemic control often transition to Ozempic. Because Ozempic has a longer half-life (~7 days vs ~5 days for dulaglutide), some physicians start Ozempic at 0.5 mg and titrate up to minimize GI side effects after switching. Always coordinate any medication change with your prescribing provider.
Why is Trulicity sometimes preferred over Ozempic despite lower efficacy?
Trulicity was the world's most-prescribed GLP-1 for several years due to its earlier approval (2014 vs 2017), established familiarity among physicians, its easy-to-use pen device, and often better insurance formulary positioning. Some patients also experience milder GI side effects on Trulicity. For patients already stable and controlled on Trulicity, switching to Ozempic purely for marginal A1C improvement may not be necessary. Formulary coverage and cost-sharing can also make Trulicity the pragmatic choice.
Is there a generic for Trulicity or Ozempic?
As of 2026, neither Trulicity nor Ozempic has an approved generic. Trulicity's patent is expected to expire around 2027, and biosimilar development is underway. Ozempic's patent protection extends further (~2030 for the injection). Some manufacturers are developing semaglutide biosimilars for global markets. Compounded semaglutide from 503B pharmacy facilities remains in a legal gray area following the FDA's removal from the shortage list. Consult your pharmacist about current generic and compounding availability in your region.

Explore next